Media headlines about Amicus Therapeutics (NASDAQ:FOLD) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amicus Therapeutics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.8055642266147 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Amicus Therapeutics, Inc. (FOLD) Sees Large Drop in Short Interest (americanbankingnews.com)
- Here is Risky Stock That May Deliver higher returns:: Amicus Therapeutics, Inc. (FOLD) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Hot Stock in the Spotlight – Amicus Therapeutics Inc (NASDAQ: FOLD) – Alpha Beta Stock (alphabetastock.com)
- Signals from Technical Perspective – Amicus Therapeutics Inc (NASDAQ: FOLD) – Alpha Beta Stock (alphabetastock.com)
- Robert W. Baird Analysts Give Amicus Therapeutics (FOLD) a $20.00 Price Target (americanbankingnews.com)
Several equities research analysts have issued reports on the company. Leerink Swann raised their price target on Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a report on Thursday. Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday. ValuEngine raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research raised Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 17th. Finally, BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Amicus Therapeutics currently has an average rating of “Buy” and a consensus price target of $19.06.
In other news, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction on Friday, December 1st. The stock was sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the sale, the insider now owns 69,184 shares of the company’s stock, valued at $940,210.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Bradley L. Campbell sold 32,500 shares of Amicus Therapeutics stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $15.92, for a total value of $517,400.00. Following the sale, the chief operating officer now directly owns 186,600 shares of the company’s stock, valued at approximately $2,970,672. The disclosure for this sale can be found here. Insiders have sold a total of 250,390 shares of company stock valued at $3,620,581 in the last ninety days. Insiders own 3.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Amicus Therapeutics (FOLD) Receiving Somewhat Positive News Coverage, Study Finds” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/02/10/amicus-therapeutics-fold-receiving-somewhat-positive-news-coverage-study-finds.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.